Fencamfamine prodrug - Praxis Bioresearch
Alternative Names: PRX P4 003Latest Information Update: 14 Aug 2025
At a glance
- Originator Praxis Bioresearch
- Class Amines; Behavioural disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Attention-deficit hyperactivity disorder; Behavioural disorders
- Preclinical Traumatic brain injuries
- No development reported Binge-eating disorder
Most Recent Events
- 11 Aug 2025 Phase-I clinical trials in Attention-deficit hyperactivity disorder (PO) prior to August 2025 (Praxis Bioresearch pipeline, August 2025)
- 11 Aug 2025 Phase-I clinical trials in Behavioural disorders (PO) prior to August 2025 (Praxis Bioresearch pipeline, August 2025)
- 11 Aug 2025 Preclinical trials in Traumatic brain injuries in USA (PO) prior to August 2025 (Praxis Bioresearch pipeline, August 2025)